Amendments to the claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1.-63. (Canceled)

64. (new) A compound of the formula (I):



or a salt, N-oxide or solvate thereof;

wherein

X is CR^5 or N;

A is a bond or $-(CH_2)_m-(B)_n-$;

B is C=O, $NR^g(C=O)$ or O(C=O) wherein R^g is hydrogen or C_{1-4} hydrocarbyl optionally substituted by hydroxy or C_{1-4} alkoxy;

m is 0, 1 or 2;

n is 0 or 1;

R^1 is hydrogen, a carbocyclic or heterocyclic group having from 3 to 12 ring members, or an optionally substituted C_{1-8} hydrocarbyl group;

R^2 is hydrogen, halogen, methoxy, or a C_{1-4} hydrocarbyl group optionally substituted by halogen, hydroxyl or methoxy;

R^3 and R^4 are the same or different and each is selected from hydrogen, CN, $C(O)R^8$, optionally substituted C_{1-8} hydrocarbyl and carbocyclic or heterocyclic groups having from 3 to 12 ring members; and

R^5 is hydrogen, a group R^2 or a group R^{10} wherein R^{10} is selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di-

C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R^a-R^b wherein R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2, NR^c, SO_2NR^c or NR^cSO_2; and R^b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NR^c, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;

R^c is selected from hydrogen and C_{1-4} hydrocarbyl;

X^1 is O, S or NR^c and X^2 is =O, =S or $=NR^c$; and

R^8 is selected from OR^{11}, SR^{11} and $NR^{12}R^{13}$;

R^{11} is selected from optionally substituted C_{1-8} hydrocarbyl and carbocyclic or heterocyclic groups having from 3 to 12 ring members; and

one of R^{12} and R^{13} is a group R^{11} and the other of R^{12} and R^{13} is hydrogen or C_{1-4} alkyl; or R^{12} and R^{13} and the nitrogen atom to which they are attached together form a saturated heterocyclic group having from 4 to 7 ring members and containing 1, 2 or 3 heteroatom ring members selected from N, O and S.

65. (new) A compound according to claim 64 wherein X is N.

66. (new) A compound according to claim 64 wherein m is 0 or 1, n is 1 and B is C=O.

67. (new) A compound according to claim 64 wherein R^2 is hydrogen, fluorine or methyl, preferably hydrogen.

68. (new) A compound according to claim 64 wherein R^1 is a monocyclic or bicyclic aryl or heteroaryl group of 3 to 12 ring members which is unsubstituted or substituted by one or more substituent groups R^{10} as defined in claim 64.

69. (new) A compound according to claim 68 wherein the aryl or heteroaryl group R^1 is selected from phenyl, pyrazolo[1,5-a]pyridinyl, furanyl, indolyl, oxazolyl,

thiazolyl, isoxazolyl, pyrrolyl, pyridyl, quinolinyl, 2,3-dihydro-benzo[1,4]dioxine, benzo[1,3]dioxole, 2,3-dihydrobenzofuranyl, imidazolyl and thienyl; each optionally substituted by one or more substituent groups R^{10} as defined in claim 64.

70. (new) A compound according to claim 69 wherein the aryl or heteroaryl group R^1 is unsubstituted or is substituted by one or more substituent groups selected from the group R^{10a} consisting of halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, heterocyclic groups having 5 or 6 ring members and up to 2 heteroatoms selected from O, N and S, a group R^a-R^b wherein R^a is a bond, O, CO, $X^3C(X^4)$, $C(X^4)X^3$, $X^3C(X^4)X^3$, S, SO, or SO_2, and R^b is selected from hydrogen, heterocyclic groups having 5 or 6 ring members and up to 2 heteroatoms selected from O, N and S, and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having 5 or 6 ring members and up to 2 heteroatoms selected from O, N and S; wherein one or more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, $X^3C(X^4)$, $C(X^4)X^3$ or $X^3C(X^4)X^3$; X^3 is O or S; and X^4 is =O or =S.

71. (new) A compound according to claim 64 wherein R^1 is a group as set out in Table 1:

Table 1

 A1	 A2	 A3	 A4
 A5	 A6	 A7	 A8

Table 1

 A9	 A10	 A11	 A12
 A13	 A14	 A15	 A16
 A17	 A18	 A19	 A20
 A21	 A22	 A23	 A24
 A25	 A26	 A27	 A28
 A29	 A30	 A31	 A32
 A33	 A34	 A35	 A36

Table 1

 A37	 A38	 A39	 A40
 A41	 A42	 A43	 A44
 A45	 A46	 A47	 A48
 A49	 A50	 A51	 A52
 A53	 A54	 A55	 A56
 A57	 A58	 A59	 A60

Table 1

 A61	 A62	 A63	

72. (new) A compound according to claim 71 wherein R^1 is selected from groups A1, A3, A61, A62 and A63 in Table 1 of claim 71 (and more preferably A1).

73. (new) A compound according to claim 64 wherein:

(A) one or both of R^3 and R^4 is or are other than hydrogen and is or are selected from optionally substituted C_{1-8} hydrocarbyl and an optionally substituted carbocyclic or heterocyclic group selected from phenyl, naphthyl, thienyl, isoxazolyl, pyridyl, 2,3-dihydro-benzo[1,4]dioxine; or

(B) one of R^3 and R^4 is an optionally substituted group selected from phenyl, naphthyl, thienyl, isoxazolyl, pyridyl, 2,3-dihydro-benzo[1,4]dioxine, and the other one of R^3 and R^4 is an optionally substituted C_{1-8} hydrocarbyl group;

wherein the optional substituents in (A) and (B) for the carbocyclic or heterocyclic groups are selected from the groups R^{10} and R^{10a} as defined in claim 64 or claim 70; and

wherein the optionally substituted C_{1-8} hydrocarbyl group (A) and (B) is selected from:

(i) C_{1-4} alkyl, hydroxy-C_{1-4} alkyl and C_{2-4} alkenyl; and

(ii) a C_{1-8} hydrocarbyl group optionally substituted by a substituent selected from optionally substituted monocyclic carbocyclic and heterocyclic groups, $NR^{12}R^{13}$, C_{1-4} alkoxy, halogen, hydroxy, C_{1-4} alkylsulphonylamino, amino, mono- and di-C_{1-4} alkylamino, wherein the alkyl residues of the C_{1-4} alkoxy, mono- and di-C_{1-4} alkylamino

groups may themselves be further substituted by a substituent selected from $NR^{12}R^{13}$, C_{1-4} alkoxy, hydroxy, C_{1-4} alkylsulphonylamino, amino, and mono- and di-C_{1-4} alkylamino, wherein R^{12} and R^{13} are as defined in claim 64, and wherein the optional substituents for the carbocyclic and heterocyclic groups are selected from the group R^{10} as defined in any one of the preceding claims; or

(C) one of R^3 and R^4 is a group $C(O)NR^{12}R^{13}$ wherein R^{12} and R^{13} and the nitrogen atom to which they are attached together form a saturated heterocyclic group having from 4 to 7 ring members and containing 1, 2 or 3 heteroatom ring members selected from N, O and S; or

(D) R^3 and R^4 are the same or different and are selected from C_{1-4}alkyl groups optionally substituted by halogen, hydroxy or methoxy.

74. (new) A compound according to claim 64 wherein the imidazole group



is selected from the groups B1 to B40 set out in Table 2:

Table 2 – Examples of the Imidazole Group



		
B1	B2	B3

Table 2 – Examples of the Imidazole Group



 B4	 B5	 B6
 B7	 B8	 B9
 B10	 B11	 B12
 B13	 B14	 B15

Table 2 – Examples of the Imidazole Group



 B16	 B17	 B18
 B19	 B20	 B21
 B22	 B23	 B24
 B25	 B26	 B27

Table 2 – Examples of the Imidazole Group



 B28	 B29	 B30
 B31	 B32	 B33
 B34	 B35	 B36
 B37	 B38	 B39

Table 2 – Examples of the Imidazole Group



 B40	 B41	

75. (new) A compound according to claim 74 wherein the imidazole group is (i) selected from the groups B1 to B6, B8, B9 and B11 to B16 of Table 2, or is (ii) selected from B18, B19, B20, B22, B24, B25, B26, B27, B28, B29, B31, B34, B35, B37 and B38; or is (iii) selected from the groups B1 to B6, B8, B9, B11 to B13, B15 and B16; or is (iv) selected from the groups B2, B4, B12, B15 and B16.

76. (new) A compound according to claim 64 in the form of a salt or solvate.

77. (new) A pharmaceutical composition comprising a compound of the formula (I) as defined in claim 64 and a pharmaceutically acceptable carrier.

78. (new) A method for the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase, which method comprises administering to a subject in need thereof a compound of the formula (I) as defined in claim 64.

79. (new) A method according to claim 78 wherein the disease state or condition is selected from proliferative disorders, viral infections, autoimmune diseases and neurodegenerative diseases.

80. (new) A method according to claim 79 wherein the proliferative disorder is a cancer selected from breast cancer, ovarian cancer, colon cancer, prostate cancer, oesophageal cancer, squamous cancer, and non-small cell lung carcinomas.

81. (new) A method of modulating a cellular process by inhibiting the activity of a cyclin dependent kinase using a compound of the formula (I) as defined in claim 64.

82. (new) A method for treating a disease or condition comprising or arising from abnormal cell growth in a mammal, which method comprises administering to the mammal a compound of formula (I) as defined in claim 64 in an amount effective to inhibit abnormal cell growth.

83. (new) A method for the prophylaxis or treatment of a disease state or condition mediated by glycogen synthase kinase-3, which method comprises administering to a subject in need thereof a compound of the formula (I) as defined in claim 64.